• Keine Ergebnisse gefunden

Reactions 1871, p241 - 4 Sep 2021

N/A
N/A
Protected

Academic year: 2022

Aktie "Reactions 1871, p241 - 4 Sep 2021"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Reactions 1871, p241 - 4 Sep 2021

Measles-mumps-and-rubella-virus-vaccine

S Aseptic meningitis: case report

A 31-year-old man developed aseptic meningitis during treatment with measles-mumps-and-rubella-virus-vaccine.

The man with no former medical and surgical history presented to the emergency room with an acute headache for 5 days in 2020. He noticed symptoms initially while lifting weights at the gymnasium. The headache was localised frontally. The pain was described as sharp and non-pulsating in nature and 10/10 in intensity. It worsened gradually, and was associated with nausea and one episode of nonbilious, non-bloody vomiting. He took over-the-counter unspecified NSAIDs for the headaches with no significant improvement. He denied any recent trauma, viral illness, sick contacts, blurred vision, photophobia, diplopia, tinnitus, hearing loss, neck stiffness, ataxia, focal motor or sensory, neurological deficits, fever, cough, chills, abdominal or chest pain, alteration in bowel habits, personal or family history of stroke and autoimmune diseases. He had been healthy and took no medications. He was up to date with his vaccinations, and received his measles-mumps-and-rubella-virus-vaccine [Merck Pharmaceuticals; route and dosage not stated] in the previous week as part of his workplace requirement. He reported two dermatomal varicella-zoster virus infection episodes in the past, first during childhood and second at 29 years. There were no other complications, and the recovery was uneventful. On physical examination, he appeared uncomfortable and complained of a persistent frontal headache. Vitals were found within normal limits, and physical examination was found unremarkable without any dermatomal rash. Signs of meningeal irritation were found negative. A COVID-19 PCR and COVID-19 antibody testing were also negative. A CT head and CT angiogram head and neck were unremarkable. Lumbar puncture was performed, which revealed elevated proteins and mononuclear cells with a lymphocytic predominance on initial studies suggestive of viral meningitis.

The man received empiric overage of aciclovir [acyclovir] and ceftriaxone based on cytology of lumbar puncture studies. He reported an improvement of his symptoms on hospital day 2 with an appropriate pain control regimen. A CSF PCR studies were positive for Varicella-zoster virus PCR and negative for Herpes Simplex Virus 1 and 2. A final diagnosis of measles-mumps-and- rubella-virus-vaccine-induced aseptic meningitis [duration of treatment to reaction onset not stated]. Varicella-zoster virus IgG came back positive. Aciclovir with appropriate hydration was continued. His headache resolved gradually, and he was discharged home on hospital day 4 with acyclovir. He was followed up after discharge, and was doing well with complete resolution of symptoms.

Sahra S, et al. Case report: aseptic meningitis secondary to varicella-zoster virus (VZV) without an exanthem post MMR vaccination. BMC Infectious Diseases 21: 746, No.

1, Dec 2021. Available from: URL: http://www.biomedcentral.com/bmcinfectdis/ 803592249

1

Reactions 4 Sep 2021 No. 1871 0114-9954/21/1871-0001/$14.95 Adis © 2021 Springer Nature Switzerland AG. All rights reserved

Referenzen

ÄHNLICHE DOKUMENTE

Ten days later, he presented due to left-sided lower motor neuron facial weakness, initially House Brackmann grade III.. He was diagnosed with

In a retrospective study conducted in southern India hospital involving healthcare workers, who received prophylactic hydroxychloroquine between June 2020 to July 2020, a patient

An 80-year-old woman developed worsening of COVID-19 pneumonia following treatment with methylprednisolone and prednisone for relapsed ulcerative colitis (UC) [durations of

Case 3: The 60-year-old woman, who had family history of thrombosis and medical history of hyperlipidaemia, diabetes mellitus and hypertension, presented eight days after the

In a retrospective study of prospectively collected data within an ongoing, non-interventional, multicenter, observational cohort study (Italian PBC Registry) of 191 patients

A 72-year-old woman developed idiopathic thrombocytopenic purpura following administration of mRNA-1273 Covid-19 vaccine.. The woman received the first dose of the mRNA-1273

In a clinical chart review and post-mortem examination from a retrospective monocentric study (COVIDAge study) involving 264 patients aged 75 years and older and

A 20-year-old woman developed COVID-19 respiratory infection and Mycobacterium tuberculosis infection during immunosuppressant drug therapy with dimethyl fumarate for